STTT：任贺/路国涛团队揭示脂肪肝促进胰腺癌的新机制，并提出治疗新靶点

Core Viewpoint - The study highlights that Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) accelerates the progression and metastasis of Pancreatic Ductal Adenocarcinoma (PDAC) through the macrophage migration inhibitory factor-CD44 axis [5][8]. Group 1: Research Findings - MASLD significantly increases the overall risk of PDAC, with a risk ratio of 3.48 observed in the population with MASLD [7]. - A strong correlation between MASLD and liver metastasis was confirmed in clinical cohort studies, with an odds ratio of 7.06 [7]. - Experimental mouse models demonstrated that MASLD enhances tumor cell stemness, immune evasion, and the formation of cell adhesion plaques in metastatic liver tissue [7]. Group 2: Mechanism and Implications - MASLD-induced MIF secretion promotes the migration, stemness, and adhesion of CD44-positive PDAC cells [8]. - Targeting MIF through genetic means or using the MIF isomerase inhibitor IPG1576 significantly reduced liver metastasis in preclinical models [8]. - The study emphasizes the MIF-CD44 signaling axis as a promising therapeutic target and the importance of developing personalized treatment plans for PDAC patients with concurrent MASLD [8].